-
48 8.0
Immune-mediated toxicities (irAEs) in immune checkpoint inhibitor (ICI) therapy in various combinations: a real-world sample
-
46 5.8
Clinical characterization and association with autoimmunity in immune checkpoint inhibitor (ICI)-mediated thyroid dysfunction in a real-world sample
-
49 4.75
Predicting immune-related adverse events (irAEs) with large language model (LLM) embeddings